HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - The Census and Statistics Department today released the latest external merchandise trade statistics. In February 2026, the total value of merchandise exports increased by 24.7% year-on-year to $408.8 billion. For the first two months of 2026, the total value of exports of goods amounted to $928.3 billion, marking an increase of 29.6% from the same period of last year.Hong Kong Trade Development Council’s Director of Research Bruce Pang said, over the past few months, Hong Kong’s external trade has continued to exhibit clear growth momentum. Although global geopolitical conditions remain tense, underlying demand from the Chinese Mainland and major overseas markets has remained resilient. We maintain a positive outlook, yet remain cautious in regard to Hong Kong’s trade performance.”HKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Jane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, N.Y., Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - OpenClawd AI today released a security-focused platform update that adds automated skill vetting, verified installer sourcing, and runtime sandboxing to its managed OpenClaw hosting service. The update responds to two converging threats targeting users of the open-source AI agent formerly known as Clawdbot and Moltbot: a large-scale malware campaign inside the official OpenClaw skill marketplace, and a parallel wave of counterfeit installation packages being promoted through search engine results.The numbers are bad enough on their own. Together, they describe a supply chain that is actively hostile to casual users.One in Eight OpenClaw Skills Is Confirmed MaliciousIndependent security researchers recently completed an audit of the ClawHub skill marketplace — the primary distribution channel for third-party OpenClaw plugins. Out of 2,857 published skills, 341 were confirmed as malicious. That is approximately 12% of the entire marketplace.The findings include:Keyloggers and credential stealers deployed through skills that appear to offer legitimate productivity featuresSilent data exfiltration — one widely-downloaded skill was found to instruct the OpenClaw agent to execute curl commands that sent user data to an external server without any notification or consent promptPrompt injection payloads embedded in skill descriptions, designed to override the agent’s safety guidelines and force execution of unauthorized commandsPlaintext credential exposure — a separate audit found that over 280 additional skills were leaking API keys, tokens, and passwords in their source codeA major cybersecurity firm tested a specific ClawHub skill and published the results: nine security findings, including two critical and five high-severity issues. The skill functioned as what the researchers called “functionally malware.” The most widely-downloaded malicious skill on ClawHub was a cryptocurrency stealer.Fake OpenClaw Installers Are Being Promoted by Search EnginesThe marketplace problem is only half the story. A cybersecurity research team discovered that threat actors have published counterfeit OpenClaw installation packages on open-source code repositories. These fake installers mimic the legitimate OpenClaw setup process but instead deliver a malware packer that disables firewall protections and routes network traffic through compromised systems.The attack chain is straightforward: a user searches for “install OpenClaw” or “Clawdbot download.” An AI-powered search engine returns a result linking to the malicious repository. The user follows the instructions. The malware deploys silently.The researcher who discovered the campaign noted that the person who first reported the threat was a technical professional. “If a fellow IT pro is susceptible to this threat,” he said, “then anyone could be.”“There are now two ways to get compromised before you even run your first OpenClaw command,” said Danny Wilson, spokesperson for OpenClawd. “You can install a fake version of the software, or you can install the real version and then add a skill that steals your data. We built this update so that neither path exists on our platform.”What OpenClawd Ships TodayThis update targets both the supply chain and the runtime:Verified installer sourcing — all OpenClawd instances are provisioned from cryptographically signed OpenClaw releases, pulled directly from the official repository. No third-party install paths. No search engine intermediaries.Skill vetting pipeline — third-party skills go through automated static analysis and behavioral testing before activation. Skills flagged for network exfiltration, prompt injection patterns, or credential exposure are blocked by default.Runtime sandboxing — each skill executes in an isolated environment with explicit permission boundaries. A skill that requests network access to an unexpected endpoint triggers a review before execution.Credential isolation — API keys and tokens are stored in encrypted vaults and never exposed in plaintext to skill code or agent logsAutomatic CVE patching — hosted instances track the latest stable OpenClaw release (currently v2026.3.x), with all known vulnerabilities patched before deploymentOpenClawd does not operate its own skill marketplace. Skills available on hosted instances are drawn from the official ClawHub repository after passing the vetting pipeline described above.OpenClawd is not affiliated with the OpenClaw open-source foundation, OpenAI, Peter Steinberger, or any third-party security research firm cited in this release. It is an independent platform built on the open-source Clawdbot codebase. The open-source project remains free at github.com/openclaw/openclaw.Pricing starts with a free tier. Paid plans include dedicated compute, priority security patching, and uptime monitoring. Deploy a secure OpenClaw instance at https://openclawd.ai.Contact:Email: support@openclawd.ai  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Development Highlights- During the Year, the Group had 4 innovative products approved for marketing by the NMPA, namely, Saitanxin(R) (Culmerciclib Capsules), Hernexeos(R) (Zongertinib Tablets), Putanning(R) (Meloxicam Injection (II)) and Anqixin(R) (Recombinant Human Coagulation Factor VIIa N01 for Injection).- In 2025, the Group’s sales of innovative products reached RMB 15.22 billion, representing a year-on-year increase of 26.2%. In addition, the Group has established multiple R&D centers in Shanghai, Nanjing, Beijing, Guangzhou, and other cities, and has successfully built diversified innovative technology platforms covering small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalable formulations, transdermal patches and other fields.- As at 31 December 2025, the Group had a total of 39 innovative oncology drug candidates, 10 innovative liver/cardiometabolic drug candidates, 14 innovative respiratory/autoimmune drug candidates, and 6 innovative surgery/analgesia drug candidates in the process of clinical trial application or above. Of these, 1 innovative oncology drug candidate and 2 innovative surgery/analgesia drug candidates are in the marketing application stage; and 13 innovative oncology drug candidates, 1 innovative liver/cardiometabolic drug candidate, 5 innovative respiratory/autoimmune drug candidates, and 1 innovative surgery/analgesia drug candidate are in Phase III clinical trials. Also, 9 innovative oncology drug candidates, 6 liver/cardiometabolic drug candidates, 5 innovative respiratory/autoimmune drug candidates, and 2 innovative surgery/analgesia drug candidates are in Phase II clinical trials. In addition, the Group had a total of 16 innovative oncology drug candidates, 3 innovative liver/cardiometabolic drug candidates, 4 innovative respiratory/autoimmune drug candidates, and 1 innovative surgery/analgesia drug candidate in Phase I clinical trials.- Focus V(R) (Anlotinib Hydrochloride Capsules) is a novel small molecule multi-target tyrosine kinase inhibitor that has been approved for 10 indications. It has several new indications currently in Phase III clinical studies, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, with plans to gradually submit marketing applications within the next two years.- From 2023 to 2025, the Group obtained marketing approval for 7 national category 1 innovative oncology drugs, namely, Saitanxin(R) (Culmerciclib capsule), Hernexeos(R) (Zongertinib table), Yilishu(R) (Efbemalenograstim alfa Injection), Andewei(R) (Benmelstobart Injection), Anboni(R) (Unecritinib Fumarate Capsules), Anluoqing(R) (Envonalkib Citrate Capsules), and Anfangning(R) (Garsorasib Tablets). It also obtained marketing approval for 4 oncology biosimilars, including Anbeisi(R) (Bevacizumab Injection), Delituo(R) (Rituximab Injection), Saituo(R) (Trastuzumab for Injection), and Paletan(R) (Pertuzumab Injection). The sales volume of these products accelerated rapidly in 2025, and they have become important contributors to the Group’s revenue growth.- Tianqing Ganmei(R) (Magnesium Isoglycyrrhizinate Injection) is the fourth-generation of glycyrrhizic acid preparation that has been approved for 3 indications. During the Year, the Group made efforts to strengthen academic promotion, expanding doctor coverage and gaining recognition from experts through academic conferences at all levels, while vigorously exploring new patients to expand into new markets, and actively promoting retrospective research to provide more academic evidence for its clinical use.- TQC3721 (PDE3/4 inhibitor) is a dual PDE3/4 inhibitor currently undergoing Phase III clinical trials in China for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). The Group is developing a variety of dosage forms of TQC3721: a suspension for inhalation is in Phase III clinical trials, and an inhaled dry powder formulation is in Phase II clinical trials. The different dosage forms are expected to further enhance patient compliance.- Zepolas(R)/Debaian(R) (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. The Group focuses on the development of highpotential regions, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand, driving the sustained rapid sales growth of Zepolas/Debaian. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. With formulation enhancements, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX stock code:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2025 (the “Year”).During the Year, the Group's revenue increased by approximately 10.3% to approximately RMB31.83 billion. Profit attributable to owners of the parent from continuing operations (as reported) was approximately RMB2.34 billion, a year-on-year increase of approximately 22.0%. Basic earnings per share attributable to owners of the parent from the continuing operations were approximately RMB13.02 cents, an increase of approximately 24.0% over last year. Underlying profit attributable to owners of the parent totaled approximately RMB4.54 billion, a year-on-year increase of approximately 31.4%. The Group’s liquidity remained strong, with cash and bank balances classified as current assets of approximately RMB12.18 billion, bank deposits classified as non-current assets of approximately RMB10.25 billion, wealth management products of approximately RMB10.56 billion in total, and total fund reserves of approximately RMB32.99 billion for the Year.The Board of Directors has recommended a final dividend payment of HK5 cents per share (2024: HK4 cents). Together with an interim dividend of HK5 cents already paid, the total dividend for the year amounts to HK10 cents (2024: HK7 cents).Sales: Innovation-driven growth fuels sustained sales momentumDuring the Year, the Group consistently increased investments to enhance R&D quality and efficiency, which led to a marked strengthening of R&D capabilities, driving sustained sales revenue growth and delivering substantial results. Sales of innovative products increased by 26.2% year-on-year to approximately RMB15.22 billion, accounting for approximately 47.8% of the Group’s revenue. If the sales is categorized by therapy field, sales of oncology drugs increased by 22.8% year-on-year to approximately RMB13.18 billion, accounting for approximately 41.4% of the Group's revenue. Sales of surgical/analgesic medications increased by 12.8% year-on-year to approximately RMB5.03 billion, accounting for approximately 15.8% of the Group's revenue.In the field of oncology, the Group has a comprehensive layout in non-small cell lung cancer (NSCLC), covering the full-line treatment of multiple subtypes. Focus V(R) (Anlotinib Hydrochloride Capsules) has been approved for 10 indications, and several new indications are currently in the marketing application or Phase III clinical trial stage. Its combination therapy has demonstrated superior efficacy in the treatment of lung cancer. From 2023 to 2025, the Group obtained approval for and launched a total of 7 national category 1 innovative oncology drugs and 4 oncology biosimilars. The sales volume of these products accelerated rapidly in 2025, and they have become important contributors to the Group’s revenue growth.In the field of surgery/analgesia, Zepolas(R)/Debaian(R) (Flurbiprofen Cataplasms) have ranked first in market share of topical analgesia for many years. The second-generation flurbiprofen patch is anticipated to receive marketing approval within the year and is expected to strengthen its market leadership through this dosage form upgrade. Meanwhile, Putanning(R) (Meloxicam Injection (II)), China’s first once-daily long-acting analgesic NSAIDs injection, was approved for marketing by the NMPA and the FDA in May 2025 and has been included in the NRDL in 2025. It is expected to become another blockbuster product for the Group in pain management area.R&D: Technology-driven advancements significantly enhance R&D quality and efficiency R&D innovation has always been the key driving force of the Group. The Group has established multiple R&D centers in places including Shanghai, Nanjing, Beijing, and Guangzhou, and has successfully built diversified innovative technology platforms covering such fields as small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalation formulations, and transdermal patches. For the year ended 31 December 2025, the Group’s total R&D investment amounted to approximately RMB 6.32 billion, accounting for approximately 19.8% of Group revenue.The Group also attaches tremendous importance to the protection of intellectual property rights and actively files patent applications to enhance its core competitiveness. During the Year, the Group filed 1,167 new patent applications and received 273 patent grants. As at the end of the Year, the Group had accumulated 5,724 valid patent applications and obtained 2,120 valid patent grants.Prospects: Focusing on innovation and firmly promoting internationalization strategyLooking ahead, the Group will continue to focus on innovation and remain deeply committed to four core therapeutic areas – oncology, liver / cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. It will leverage AI to deeply empower the entire R&D process and continuously strengthen its R&D and innovation capabilities to drive steady business growth. Over the next three years (2026-2028), the Group’s innovation pipeline is expected to experience another wave of explosive growth, with nearly 20 national category 1 innovative drugs expected to be approved for marketing, including multiple blockbuster products with first-in-class (FIC) and best-in-class (BIC) potential. It is expected that by the end of 2028, the total number of innovative products launched by the Group will be around 40, positioning them as the core driver of business growth.At the same time, the Group will firmly advance its internationalization strategy. In February 2026, the Group announced that it had granted Sanofi an exclusive worldwide license to develop, manufacture, and commercialize Rovadicitinib, with the right to receive payments of up to US$1.53 billion, plus tiered royalties of up to double digits based on annual net sales of Rovadicitinib. Going forward, out-licensing will become another important source of revenue for the Group, continuously injecting strong, new momentum into its performance growth and formally launching a second growth curve supported by revenue from internationalization. In addition, the Group remains committed to adhering to the "win-win cooperation" philosophy and is dedicated to building an open and diverse innovation ecosystem. Through in-depth cooperation with the world's leading pharmaceutical companies, biotechnology firms and scientific research institutions, the Group is accelerating the aggregation of high-quality global resources, promoting the co-creation and sharing of innovative outcomes, and continuously strengthening its market leadership. Through the integration of high-quality resources such as LaNova Medicines and Hygieia, the Group has significantly strengthened its R&D capabilities in cutting-edge fields, including tumor immunology and siRNA.Looking ahead, the Group will continue to drive innovation through its dual engines of internal R&D and strategic cooperation, accelerate its development through internationalization, and make steady progress towards its strategic goal of becoming a world-class innovative pharmaceutical company.For detailed information on the Group’s results for the Year, please refer to the official announcements uploaded by the Group to the Hong Kong Stock Exchange website and its official website.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited, together with its subsidiaries, is a leading, innovative R&D-driven pharmaceutical group in China. Its business covers the entire industrial chain, including R&D platforms, intelligent manufacturing, and a robust sales system. Its products encompass a wide range of biologics and chemical drugs, with a strong presence in four core therapeutic areas: oncology, liver/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. The company was listed on the Hong Kong Stock Exchange in 2000, was included as a constituent of the MSCI China Index in 2013, became a constituent of the Hang Seng Index in 2018, and was added to the Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong-listed) 25 Index in 2020. The company has been named among the "Top 50 Global Pharmaceutical Companies" by the authoritative U.S. magazine Pharm Exec for seven consecutive years, and has been recognized as one of the "Top 50 Best Companies in Asia" by Forbes Asia for three consecutive years.For more information, please visit: www.sbpgroup.com  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

重點成果- 年內，集團共有4個創新產品獲NMPA批准上市，分別為賽坦欣(R)（庫莫西利膠囊）、聖赫途(R)（宗艾替尼片）、普坦寧(R)（美洛昔康注射液(II)）和安啟新(R)（注射用重組人凝血因子VIIa N01）。- 2025年，集團創新產品收入達到人民幣152.2億元，同比增長26.2%。此外，集團已在上海、南京、北京、廣州等地建立多個研發中心，並成功構建了涵蓋小分子、蛋白降解劑、siRNA、單抗／雙抗、抗體偶聯藥物（ADC）、吸入製劑、透皮貼劑等領域的多元化創新技術平台。- 截至2025年12月31日，集團共有39個腫瘤領域、10個肝病╱心血管代謝領域、14個呼吸╱自免領域、和6個外科╱鎮痛領域的創新候選藥物處於臨床申請及以上開發階段。其中，1個腫瘤領域、2個外科╱鎮痛領域產品處在上市申請階段；13個腫瘤領域、1個肝病╱心血管代謝領域、5個呼吸╱自免領域、1個外科╱鎮痛領域的創新候選藥物處於臨床III期，9個腫瘤領域、6個肝病╱心血管代謝領域、5個呼吸╱自免領域、2個外科╱鎮痛領域的創新候選藥物處於臨床II期，另有16個腫瘤領域、3個肝病╱心血管代謝領域、4個呼吸╱自免領域、1個外科╱鎮痛領域的創新候選藥物處於臨床I期。- 福可維(R)（鹽酸安羅替尼膠囊）是一款新型小分子多靶點酪氨酸激酶抑制劑，目前已獲批10項適應症，其一線非鱗狀非小細胞肺癌、一線胰腺癌等多項新適應症正在開展III期臨床研究，預計未來兩年將逐步遞交上市申請。- 2023-2025年，集團共有7款腫瘤領域的國家1類創新藥獲批上市，分別為：賽坦欣(R)（庫莫西利膠囊）、聖赫途(R)（宗艾替尼片）、億立舒(R)（艾貝格司亭α注射液）、安得衛(R)（貝莫蘇拜單抗注射液）、安柏尼(R)（富馬酸安奈克替尼膠囊）、安洛晴(R)（枸櫞酸依奉阿克膠囊）和安方寧(R)（格索雷塞片）；以及4款腫瘤領域的生物類似藥獲批上市，分別為：安倍斯(R)（貝伐珠單抗注射液）、得利妥(R)（利妥昔單抗注射液）、賽妥(R)（注射用曲妥珠單抗）和帕樂坦(R)（帕妥珠單抗注射液）。該等產品在2025年快速放量，成為集團收入增長的重要貢獻品種。- 天晴甘美(R)（異甘草酸鎂注射液）是第四代甘草酸製劑，目前已獲批3個適應症。集團年內著力加強學術推廣，透過各層級的學術會議增強了醫生覆蓋和專家認可，同時大力發掘新患者拓展新市場，並積極推進回顧性研究，為其臨床使用提供更多的學術證據。- TQC3721（PDE3／4抑制劑）是一款PDE3／4雙重抑制劑，目前正在中國開展III期臨床試驗，用於治療中重度慢性阻塞性肺病（COPD）。集團正在開發TQC3721的多種劑型：吸入用混懸液位於III期臨床階段，吸入粉霧劑位於II期臨床階段，有望透過多種劑型進一步提升患者的依從性。 - 澤普思(R)／得百安(R)（氟比洛芬凝膠貼膏）是中國首個獲批上市的國產凝膠貼膏，連續多年蟬聯外用鎮痛市場份額第一位。集團聚焦高潛力地區開發，深入拓展市場覆蓋，並逐步擴大產能以滿足市場的旺盛需求，推動澤普思／得百安銷售額持續快速增長。集團開發的第二代氟比洛芬貼劑預計將在年內獲批上市，透過劑型升級，二代產品可顯著提高藥物透皮吸收度，增強貼膏粘附性，從而提升患者的依從性。 香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 中國領先的創新研發驅動型醫藥集團-中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2025年12月31日止12個月（「年內」）之經審核財務業績。年內，集團收入增長約10.3%至約318.3億元（人民幣，下同）。來自持續經營業務之歸屬於母持有者盈利（財務報表所示）約23.4億元，按年增長約22.0%。來自持續經營業務之歸屬於母公司持有者盈利計算之每股基本盈利約人民幣13.02分，較去年增加約24.0%。歸屬於母公司持有者之基本溢利約45.4億元，按年增長約31.4%。集團流動資金保持充裕，年內有計入流動資產之現金及銀行結餘約121.8億元、計入非流動資產之銀行存款約102.5億元，理財管理產品總額約105.6億元，資金儲備總額約329.9億元。董事會建議派發末期股息每股5港仙（2024年：4港仙），連同已派發中期股息每股5港仙，全年合共派發股息每股10港仙（2024年：7港仙）。銷售：創新引領，銷售動能持續釋放年內，集團持續加大投入以提升研發質效，研發實力顯著增強，驅動銷售收入持續增長，成果豐碩。年內，創新產品之收入同比增加26.2%，達約152.2億元。至於分治療領域，抗腫瘤用藥之收入同比增加22.8%，達約131.8億元，佔集團收入約41.4%。外科／鎮痛用藥之收入同比增加12.8%，達約50.3億元，佔集團收入約15.8%。腫瘤領域，集團全面佈局非小細胞肺癌領域，覆蓋多種分型的全線治療，福可維(R)（鹽酸安羅替尼膠囊）已獲批10項適應症，多項新適應症處於上市申請或III期臨床階段，其聯合療法在肺癌治療中展現出優效。2023年至2025年間，集團共有7款腫瘤領域的國家1類創新藥以及4款腫瘤領域的生物類似藥獲批上市，該等產品在2025年快速放量，成為集團收入增長的重要貢獻品種。於外科╱鎮痛領域，澤普思(R)／得百安(R)（氟比洛芬凝膠貼膏）連續多年蟬聯外用鎮痛市場份額第一位，第二代氟比洛芬貼劑預計將在年內獲批上市，有望透過劑型升級鞏固市場領先地位。同時，中國首款一日一次長效鎮痛NSAIDs注射液普坦寧(R)（美洛昔康注射液（II））已於2025年5月獲得NMPA和FDA的上市批准，並已被新增納入2025年國家醫保藥品目錄，有望成為集團鎮痛領域的又一款重磅產品。研發：技術築基，研發質效顯著提升研發創新始終是集團的核心驅動力，集團目前已在上海、南京、北京、廣州等地建立多個研發中心，並成功構建了涵蓋小分子、蛋白降解劑、siRNA、單抗／雙抗、抗體偶聯藥物（ADC）、吸入製劑、透皮貼劑等領域的多元化創新技術平台。截至二零二五年十二月三十一日止年度，研發總投入約人民幣63.2億元，佔集團收入約19.8%。集團亦重視保護知識產權，積極申報各項專利，以提高核心競爭力。年內，集團提交專利申請1,167項、獲得專利授權273項。截至年末，集團累計有效專利申請達5,724項，累計有效專利授權達2,120項。展望：聚焦創新，堅定推進國際化戰略展望未來，集團將繼續聚焦創新，深耕腫瘤、肝病／心血管代謝、呼吸／自免、外科／鎮痛四大核心治療領域，以AI深度賦能研發全流程，持續強化創新研發能力推動業績穩步增長。預計未來三年（2026-2028年），集團創新管線將迎來新一輪爆發式增長，預計近20款國家1類創新藥有望獲批上市，涵蓋多款具備全球同類首創 (FIC) ／同類最佳 (BIC) 潛力的重磅產品。預計至2028年底，集團上市創新產品總數將達到近40款，成為驅動業績增長的核心引擎。同時，集團堅定推進國際化戰略。2026年2月，集團宣佈授予Sanofi在全球範圍內開發、生產及商業化羅伐昔替尼的獨家許可，並有權獲得最高15.3億美元的付款，以及基於羅伐昔替尼年度淨銷售額的高達雙位數的銷售提成。未來，對外授權合作將成為集團的又一重要收入來源，持續為業績增長注入強勁新動能，正式開啟以國際化收入為支撐的第二增長曲線。此外，集團始終秉持「合作共贏」理念，著力構建開放多元的創新生態體系。透過與全球頂尖藥企、生物科技公司及科研機構的深度合作，集團正加速彙聚全球優質資源，推動創新成果的共創共享，持續鞏固市場領導地位。透過整合禮新醫藥、赫吉亞等優質資源，集團在腫瘤免疫及siRNA等前沿賽道的研發實力顯著增強。未來，集團將繼續以自主研發與戰略合作雙引擎驅動創新，以國際化加速發展，向世界級創新醫藥企業的戰略目標穩步邁進。有關集團本年度詳細業績資料，請參閱集團上載至香港聯合交易所及官網之正式公告。有關中國生物製藥有限公司（股票編號：1177）中國生物製藥，連同其附屬公司，是中國領先的創新研究和研發驅動型醫藥集團，業務覆蓋醫藥研發平台、智慧化生產和強大銷售體系全產業鏈。產品包括多種生物藥和化學藥，在腫瘤、肝病／心血管代謝、呼吸／自免、外科／鎮痛四大治療領域處於優勢地位。公司於2000年在香港聯交所上市，2013年入選MSCI全球標準指數之中國指數成分股；2018年入選恒生指數成分股；2020年入選恒生滬深港通生物科技50指數成分股、恒生中國(香港上市)25指數。中國生物製藥連續七年榮登美國權威雜誌《製藥經理人》發佈的「全球製藥企業TOP50」，連續三年獲評《福布斯》(亞洲) 「亞太最佳公司50強」。有關中國生物製藥的進一步資料，請瀏覽: www.sbpgroup.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

West Palm Beach, FL, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA) founded in 1890, today announced the launch of its Global Polo Shirt Campaign, An Icon Born from the Game. The global campaign is a powerful tribute to the iconic polo shirt's authentic sports origins and its evolution into one of the world's most enduring style essentials.U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player Nico Escobar takes in the game atop his equine partner, wearing polo whites and a classic navy U.S. Polo Assn. polo shirt, An Icon Born from the GameU.S. Polo Assn. models in polo shirts at the Spring-Summer 2026 Global Collection Photoshoot in Charleston, South Carolina‘The Polo Shirt: An Icon Born From the Game' campaign imagery featuring U.S. Polo Assn. modelsThe polo shirt's beginning was born on the polo fields, shaped by motion, competition, and the spirit of the game for which it was named. From its earliest days, the polo shirt was designed with purpose, worn by players seeking performance on the polo fields. Today, U.S. Polo Assn. celebrates this timeless favorite, not just as a fashion item, but as an icon born from sport and carried forward through generations of players and consumers all over the world.The polo shirt is one of the most iconic essentials dating back over 100 years, notable for its unique fusion of sport and style. Originally designed with breathable pique knit, a soft collar, and lightweight construction to meet the demands of competitive sports, it has evolved into a timeless essential, suitable for casual elegance and leisurewear.The polo shirt traces its origins to polo players, where it was created out of necessity for the sport. Polo players modified long‑sleeved cotton shirts to better handle heat, movement, and wind while playing. These functional, sport‑driven adaptations represent the earliest form of what would become the polo shirt. In the early 20th century, polo players helped formalize these functional elements as the sport gained popularity, reinforcing the shirt's connection to the sport and its functional design.Over the years, the polo shirt became a cornerstone of casual sportswear around the world, symbolizing preppy style, luxury leisure culture, and contemporary athleisure, seamlessly transitioning from polo fields to college campuses and boardrooms. Its enduring adaptability is demonstrated by distinct reinventions across the decades; the ability to evolve has ensured the polo shirt's lasting relevance and cultural significance.As the official sports brand of the USPA, founded in 1890 and one of the oldest sports governing bodies in the United States, U.S. Polo Assn. occupies an authentic place in the history of the polo shirt."The polo shirt's DNA is deeply rooted in the inspirational sport that inspired it," said J. Michael Prince, President and CEO of USPA Global, the company that manages and markets the multi-billion-dollar, global U.S. Polo Assn. brand. "With An Icon Born from the Game, we're honoring a legacy that began on the field and continues to shape how polo players, sports fans, and consumers all over the world live, move, and express themselves today, and for future generations."An Icon Born from the Game reinforces that legacy by connecting the polo shirt's origins in the sport, while celebrating its place in modern culture."The polo shirt was designed for the game with a real purpose on the field, but it's also what I wear off the field to go out to dinner or hang out with friends and family," said Nico Escobar, U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player. "I love that U.S. Polo Assn. understands both the performance aspect and how the polo shirt fits into everyday life.""U.S. Polo Assn.'s authentic connection to the sport and the way it supports the game of polo around the world is why I wear it - both on the field and off," adds Escobar.Global Launch: An Icon Born from the GameLaunching globally across 190 countries in Spring 2026, An Icon Born from the Game will come to life through a coordinated, multi‑channel presence designed to make the U.S. Polo Assn. polo shirt unmistakably visible wherever consumers engage with the sport-inspired brand. In stores, dedicated polo shirt focus areas, including the brand's iconic polo walls, window displays, and visual merchandising moments, will highlight the full range of styles through bold color stories, clear categorization, and campaign signage anchored by the slogan.Across outdoor and print advertising, hero imagery shot on location brings the polo shirt back to the field, reinforcing its authentic connection to the sport, while digital and social media activations extend the story through short‑form content and global storytelling. Together, these touchpoints create a consistent, immersive expression of the polo shirt as a true icon rooted in sport but relevant to everyday life.Further, An Icon Born from the Game is launching around two of the sport's most important events in the United States - the prestigious USPA Gold Cup® and one of the most competitive tournaments in the world, the U.S. Open Polo Championship®, which concludes with the Championship Final on April 26."An Icon Born from the Game is about owning our truth and telling it boldly on a global scale," said Stefanie Coroalles, Vice President, Global Brand Marketing. "The Global Polo Shirt Campaign brings together heritage, product, and self-expression, showing how the polo shirt moves effortlessly from sport to everyday life.""This launch is a proud moment for us, one that brings our heritage to life in a way that feels modern, visible, and unmistakably U.S. Polo Assn.," adds Coroalles.Product Pillars: Play It Your Way"Every U.S. Polo Assn. polo shirt is designed with intention by balancing style, comfort, function, and authentic sport details," said Brian Kaminer, Senior Vice President, Brand and Product Development. "From heritage-inspired construction to modern performance fabrics, our U.S. Polo Assn. collections reflect how the polo shirt continues to evolve while staying true to its sports roots."The global polo shirt campaign showcases the versatility of the icon through five distinct expressions that give the consumer the opportunity to "Play It Your Way" when styling with the polo shirt.Play It Sporty is the polo shirt that carries the legacy of U.S. Polo Assn. in every stitch. Featuring authentic detailing, iconic branding, and sport-inspired elements, this timeless silhouette connects directly to the game that started it all. Official crests, classic cuts, and traditional design details celebrate the sport of polo's history and the brand's deep-rooted heritage.Play It Classic is the polo shirt for the moments that make up everyday life. Clean, comfortable, and easy to style, it's the go-to option when you want something that always works. Designed to be worn again and again, it fits seamlessly into any routine, whether casual, relaxed, or slightly dressed up.Play It in Motion with the performance polo shirt engineered for action. Advanced technical fabrics deliver moisture-wicking comfort, breathability, and stretch that moves with you throughout the day. Designed for polo players on the field or in life in motion, it balances durability and function with a sharp, modern look.Play It Bold is the fashion polo shirt built for self-expression. Defined by confidence and style, this version brings personality and freedom to a familiar icon. Worn casually or styled with intention, it shows how versatile the polo shirt can be when it's shaped by confidence and worn on an individual's own terms.Play It Elevated is the premium polo shirt made for moments that call for refinement. Crafted with elevated materials and thoughtful detailing, it offers a polished look without feeling formal. Clean lines and a thoughtful fit create a composed yet confident style that balances ease with sophistication.U.S. Polo Assn.'s seasonal polo shirts are offered across men's, women's, and kids' collections in an expansive range of fabrics, finishes, and colors - from classic neutrals to vibrant hues. Updated designs feature textured ribs, subtle patterns, and elevated construction details, finished with the brand's signature Double Horsemen logo - a mark of authenticity and a symbol of the sport.U.S. Polo Assn. continues to incorporate products aligned with its global sustainability program, USPA Life, reflecting the brand's commitment to responsible sourcing and long-term environmental initiatives. The USPA Life Polo Shirt, arriving in stores Spring 2027, builds on U.S. Polo Assn.'s most iconic style, designed with thoughtfully chosen, preferred materials that reflect the brand's commitment to improving the global footprint of this iconic staple. From 100% preferred cotton fabric to the finishing details like buttons and thread, each element has been selected to reduce impact while preserving the classic look, comfort, and quality customers expect from a U.S. Polo Assn. polo shirt.U.S. Polo Assn. apparel and accessories are available in U.S. Polo Assn. stores and online at uspoloassnglobal.com.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sportsin India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sports content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.For Additional Information, Contact:Stacey Kovalsky - VP, Global PR and CommunicationsPhone +954.673.1331 - E-mail: skovalsky@uspagl.comKaela Drake - Senior PR and Comms SpecialistPhone +561.530.5300 - E-mail: kdrake@uspagl.comSOURCE: U.S. Polo Assn. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛羅里達州西棕櫚灘, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 由1890年成立的美國馬球協會（USPA）所授權的官方運動品牌 U.S. Polo Assn.，今日宣布推出全球馬球衫宣傳活動「源自賽場的經典」。這項全球性活動旨在向標誌性的馬球衫致敬，彰顯其純正的運動淵源，以及它如何演變為全球最歷久彌新的時尚經典之一。U.S. Polo Assn. 全球品牌大使、6級美國職業馬球選手尼科·埃斯科巴（Nico Escobar）身著馬球白裝與經典海軍藍 U.S. Polo Assn. 馬球衫，騎乘愛駒觀賽，展現「源自賽場的經典」精神U.S. Polo Assn. 模特兒身著馬球衫，於南卡羅來納州查爾斯頓參與 2026 春夏全球系列攝影「馬球衫：源自賽場的經典」宣傳影像，由 U.S. Polo Assn. 模特兒演繹Polo衫的起源可追溯至馬球場，其設計深受運動動作、競技精神以及這項賦予其名稱的運動所塑造。自問世之初，Polo衫便以實用為本，由追求賽場表現的球員們所穿著。時至今日，U.S. Polo Assn. 不僅將這款歷久不衰的經典視為時尚單品，更視其為源自運動、並由全球數代球員與消費者共同傳承的標誌性象徵。馬球衫是擁有逾百年歷史的最具代表性經典單品之一，以其獨特的運動與時尚融合而著稱。最初採用透氣的平紋針織面料、柔軟的領口及輕量結構，以滿足競技運動的需求；如今已演變為永恆的經典單品，既適合展現休閒優雅，亦是理想的生活休閒服飾。Polo衫的起源可追溯至馬球運動員，其誕生源於這項運動的實際需求。馬球運動員為在比賽中更好地應對高溫、動作與風勢，對長袖棉質襯衫進行了改良。這些以功能性為導向的運動改裝，正是日後Polo衫的雛形。20世紀初，隨著馬球運動日益普及，運動員們協助將這些功能性元素正式化，進一步鞏固了Polo衫與這項運動及其功能性設計之間的連結。多年來，馬球衫已成為全球休閒運動服飾的基石，象徵著學院風、奢華休閒文化與當代運動休閒風，從馬球場到大學校園，再到會議室，皆能無縫融入。數十年來，馬球衫歷經多次獨特的革新，展現出其持久的適應性；這種不斷演進的能力，確保了馬球衫歷久不衰的流行地位與文化意義。作為美國馬球協會（USPA）的官方運動品牌，U.S. Polo Assn. 佔據了馬球衫歷史中獨一無二的地位。USPA 成立於 1890 年，是美國歷史最悠久的體育管理機構之一。「馬球衫的基因深深植根於那項啟發它的鼓舞人心運動，」USPA Global 總裁兼執行長 J. Michael Prince 表示。該公司負責管理並推廣這個價值數十億美元的全球性 U.S. Polo Assn. 品牌。「透過『源自賽場的傳奇』系列，我們致敬這份始於球場的傳承，它持續塑造著全球馬球選手、運動迷及消費者當下的生活、行動與自我表達方式，並將影響未來的世代。」「源自賽場的傳奇」系列透過連結馬球衫與這項運動的淵源，同時彰顯其在現代文化中的地位，進而鞏固這份傳承。「這件馬球衫是專為比賽設計，在球場上確實有其實際用途，但它也是我場下外出用餐或與親友聚會時會穿的服裝，」U.S. Polo Assn. 全球品牌大使、6級美國職業馬球選手尼科·埃斯科巴（Nico Escobar）表示。「我很欣賞 U.S. Polo Assn. 既重視機能表現，也懂得如何讓馬球衫融入日常生活。」「U.S. Polo Assn. 與這項運動的真摯連結，以及它對全球馬球運動的支持，正是我無論在場上或場下都選擇穿著它的原因，」埃斯科巴補充道。全球發佈：「源自賽場的經典」「源自賽場的經典」系列將於2026年春季在全球190個國家同步上市，透過協調一致的多渠道佈局，讓美國馬球協會的馬球衫在消費者接觸這個運動靈感品牌的任何場合都清晰可見。在實體店鋪中，專門的馬球衫展示區——包括品牌標誌性的馬球衫牆、櫥窗陳列及視覺 merchandising 亮點——將透過大膽的色彩故事、清晰的品類劃分，以及以標語為核心的活動標識，全面呈現各類款式。無論是戶外廣告還是平面廣告，現場拍攝的主視覺影像將馬球衫帶回球場，強化其與這項運動的真實連結；而數位與社群媒體的推廣活動，則透過短片內容與全球敘事延展這個故事。這些接觸點共同營造出連貫且沉浸式的呈現，彰顯馬球衫作為真正標誌性單品的特質——它植根於運動，卻也與日常生活息息相關。此外，「源自賽場的經典」活動將配合美國兩項最重要的馬球賽事同步推出——包括享有盛譽的 USPA 金盃®（USPA Gold Cup®），以及全球競爭最激烈的賽事之一「美國公開馬球錦標賽®」（U.S. Open Polo Championship®），該賽事將於 4 月 26 日舉行冠軍決賽。「『源自賽場的經典』旨在擁抱我們的真實本質，並在國際舞台上大膽傳遞這份精神，」全球品牌行銷副總裁史蒂芬妮·科羅亞萊斯（Stefanie Coroalles）表示。「這場全球馬球衫宣傳活動融合了品牌傳承、產品特色與自我表達，展現了馬球衫如何從運動場域無縫融入日常生活。」「此次發布對我們而言是值得驕傲的時刻，它以現代、鮮明且無可辯駁的 U.S. Polo Assn. 風格，將我們的傳承賦予新生，」科羅亞萊斯補充道。產品核心理念：隨心所欲，盡情展現「每一件 U.S. Polo Assn. 馬球衫皆經過精心設計，在風格、舒適度、功能性與純正運動細節之間取得完美平衡，」品牌與產品開發資深副總裁布萊恩·卡米納（Brian Kaminer）表示。「從汲取傳統靈感的剪裁到現代機能面料，我們的 U.S. Polo Assn. 系列展現了馬球衫如何在忠於運動本源的同時，持續演進。」這場全球馬球衫宣傳活動透過五種獨特風格，展現這款經典單品的百變魅力，讓消費者在搭配馬球衫時，能盡情「隨心所欲，盡情展現」。「運動風」系列（Play It Sporty）的每一針每一線都承載著 U.S. Polo Assn. 的傳承。憑藉純正的細節、標誌性的品牌標識以及受運動啟發的元素，這款永恆的剪裁直接連結了品牌起源的馬球運動。官方徽章、經典剪裁與傳統設計細節，共同致敬馬球運動的歷史與品牌深厚的傳承。「Play It Classic」系列專為日常生活的點滴時刻而生。簡約、舒適且易於搭配，是您尋求百搭之選時的首選。這款專為反覆穿著而設計的 polo 衫，無論是休閒、放鬆或稍作打扮的場合，都能完美融入您的日常。「Play It in Motion」系列，專為動態活動打造的高性能POLO衫。採用先進技術面料，具備吸濕排汗的舒適感、透氣性及彈性，全天候隨您的動作靈活伸展。無論是球場上的POLO球員，還是追求動態生活的您，這款設計皆能兼顧耐用性與功能性，同時展現俐落現代的風格。「Play It Bold」系列，是專為自我表達而生的時尚POLO衫。這款作品以自信與風格為核心，為這款經典單品注入個性與自由。無論是隨性穿著或精心搭配，它都展現了當Polo衫由自信塑造、並依個人風格穿出時，其多變的魅力。「Play It Elevated」是為講究精緻的時刻打造的頂級Polo衫。採用高級面料與細膩工藝，呈現出精緻外觀卻不顯拘謹。簡潔的線條與貼合的剪裁，營造出沉穩而自信的風格，完美平衡了舒適與優雅。U.S. Polo Assn. 的季節性馬球衫涵蓋男裝、女裝及童裝系列，提供豐富多樣的面料、質感與色彩選擇——從經典中性色到鮮豔色調一應俱全。全新設計採用立體羅紋、低調圖案及精緻的工藝細節，並飾以品牌標誌性的「雙騎士」標誌——這不僅是正品的保證，更是這項運動的象徵。U.S. Polo Assn. 持續推出符合其全球永續發展計畫「USPA Life」的產品，體現品牌對負責任採購及長期環保倡議的承諾。將於 2027 年春季上市的 USPA Life 馬球衫，以 U.S. Polo Assn. 最具標誌性的款式為基礎，採用經過深思熟慮挑選的優質面料，彰顯品牌致力於改善這款經典單品對全球環境影響的決心。從 100% 優質棉面料到鈕扣與縫線等細節處理，每個環節皆經過精心挑選，在降低環境影響的同時，仍完整保留顧客對 U.S. Polo Assn. 馬球衫所期待的經典外觀、舒適度與品質。U.S. Polo Assn. 的服飾與配件現已於 U.S. Polo Assn. 實體門市及官網 uspoloassnglobal.com 販售。關於 U.S. Polo Assn. 與 USPA GlobalU.S. Polo Assn. 是美國馬球協會（USPA）的官方運動品牌。USPA 成立於 1890 年，是美國規模最大的馬球俱樂部與馬球選手組織。憑藉數十億美元的全球業務規模，以及透過超過 1,200 家 U.S. Polo Assn. 零售店和數千個其他銷售據點的全球分銷網絡，U.S. Polo Assn. 在全球 190 多個國家為男女及兒童提供服飾、配件和鞋類產品。該品牌贊助全球各大馬球賽事，包括每年於棕櫚灘的 NPC 舉辦的「美國公開馬球錦標賽®」（U.S. Open Polo Championship®），此為美國首屈一指的馬球錦標賽。透過與美國 ESPN、歐洲 TNT 和 Eurosport 以及印度 Star Sports 簽訂的歷史性合作協議，由 U.S. Polo Assn. 贊助的多項世界頂級馬球錦標賽現已透過電視轉播，讓全球數百萬體育迷首次得以欣賞這項令人熱血沸騰的運動。根據《License Global》的報導，U.S. Polo Assn. 一直與 NFL、PGA 巡迴賽及一級方程式賽車並列為全球頂尖的運動授權商之一。此外，這個以運動為靈感的品牌更因全球業務成長及運動內容而獲得國際獎項肯定。憑藉其作為全球品牌的巨大成功，U.S. Polo Assn. 曾獲《富比世》、《財星》、《現代零售》及《GQ》等媒體報導，並登上雅虎財經與彭博社等全球眾多知名媒體平台。欲了解更多資訊，請造訪 uspoloassnglobal.com 並追蹤 @uspoloassn。USPA Global 是美國馬球協會（USPA）的子公司，負責管理市值數十億美元的運動品牌 U.S. Polo Assn.。USPA Global 同時管理其子公司 Global Polo，該公司是全球馬球運動內容的領導者。欲了解更多資訊，請造訪 globalpolo.com 或 YouTube 上的 Global Polo 頻道。如需更多資訊，請聯絡：Stacey Kovalsky - 全球公關與傳播副總裁電話 +954.673.1331 - 電子郵件：skovalsky@uspagl.com  凱拉·德雷克（Kaela Drake） - 資深公關與傳播專員電話 +561.530.5300 - 電子郵件：kdrake@uspagl.com 消息來源：U.S. Polo Assn. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月26日 - (亞太商訊 via SeaPRwire.com) - 聚焦於腫瘤治療領域的創新型生物製藥公司──樂普生物科技股份有限公司(「樂普生物」或「公司」，股份代號：2157.HK)公佈2025年全年業績。報告期內，公司業務及收入現強勁增長，首年實現盈利，全球首創EGFR靶向ADC美佑恆®獲批上市，核心產品商業化提速，多項國際授權合作順利推進。於報告期內，樂普生物收入實現顯著增加，總收入約為人民幣934.9百萬元，約為2024年收入的2.5倍。其中在國內商業化方面，普佑恆®（普特利單抗注射液）及美佑恒®（注射用維貝柯妥塔單抗）的收入約人民幣501.0百萬元，同比大幅增加66.8%；在許可業務方面，實現收入約人民幣424.2 百萬元，主要來自MRG007及TCE資產的對外授權。同時，公司首年實現盈利約人民幣261.4百萬元，較2024年大幅增加。經營現金流量持續向好，現金及現金等價物約為人民幣8.53億元，為2024年的兩倍以上。研發開支約人民幣4億元，較2024年同期下降8.5%，在保障核心管線推進的同時，成本控制成效顯現。核心產品商業化提速 兩項國際授權合作順利落地作為一家立足中國、面向全球的聚焦於腫瘤治療領域（尤其是靶向治療及免疫治療）的創新型生物製藥企業，樂普生物致力於通過全面且先進的ADC技術開發平台開發創新型ADC，並旨在開發出優化、創新的藥物，更好地填補癌症患者的臨床需求缺口。公司致力於通過充分整合自主創新能力及戰略合作，持續開發市場差異化產品管線。隨着ADC候選藥物進入商業化階段，公司已建立並正在逐步擴大內部生產能力以滿足業務發展的需求。目前，樂普生物已戰略性佈局了多個腫瘤產品管線。截至公告日期，公司擁有(i)兩種臨床/商業化階段候選藥物；(ii)八種臨床階段候選藥物，包括一種透過合營企業共同開發的藥物；及(iii)五種候選藥物的臨床階段聯合療法。公司有兩種候選藥物已就其靶向適應症獲得上市批准，其他適應症的臨床試驗正在進行中。在八種臨床階段候選藥物中，六種為靶向療法藥物，兩種為免疫治療藥物（分別為一種溶瘤病毒藥物及T細胞激動性抗體）。截至報告期末，通過國內商業化及業務開發活動，樂普生物在研發能力變現方面取得重要里程碑。普佑恆®（普特利單抗注射液）已完成商業化全流程，目前正處於銷售快速增長階段。憑藉這一勢頭，公司旨在優化美佑恆®（注射用維貝柯妥塔單抗）(FIC EGFR-ADC)的商業化策略，以推動更有效的市場滲透及增長。此外，另有兩款產品CMG901及MRG007也通過業務開發活動成功達成授權合作。CMG901的全球權益已授權予AstraZeneca，MRG007的大中華區以外地區權益已授權予ArriVent。多管線产品進入關鍵階段 創新ADC潛力釋放於2025年，樂普生物的全球首創EGFR靶向ADC美佑恆®已在中國獲得上市批准。同時，我們有更多候選藥物進入關鍵臨床階段，且通過開發及優化聯合治療方案實現了治療線數前移。CMG901(CLDN 18.2-ADC)：AstraZeneca於2023年2平台月獲授CMG901 (AZD0901)的研究、開發、註冊、生產及商業化獨家全球許可。AstraZeneca正積極進行CMG901的兩項III期臨床試驗：一項作為晚期/ 轉移性胃或胃食管連接部腺癌的單一療法，另一項作為與卡培他濱（伴有或不伴有rilvegostomig）聯合治療CLDN 18.2陽性和HER2陰性晚期/轉移性胃、胃食管連接部或食管腺癌的一線治療。根據許可協議，聯合試驗中首名患者的給藥已觸發45百萬美元的里程碑付款，該付款由AstraZeneca支付。MRG004A (TF-ADC)：目前正在中國進行治療PDAC的III期臨床試驗。於2025年8月，MRG004A獲國家藥監局CDE授予BTD。PC的Ib期擴展階段良好數據已於2025年ESMO大會上呈現。CG0070（溶瘤病毒）：目前公司的美國合作夥伴CG Oncology正進行CG0070的MRCT III期臨床研究。觀察到的最新良好數據已於第26屆SUO年會上作為LBA以口頭匯報形式呈現。截至2025年12月31日，公司已啟動國內關鍵臨床試驗的患者入組。此外，CG0070於2025年獲國家藥監局CDE授予BTD。MRG001 (CD20-ADC)：公司正在進行一項II期臨床研究，以評估MRG001聯合BTK抑制劑治療DLBCL患者的療效，該研究的良好中期數據已於第67屆ASH年會上呈現。MRG006A (GPC3-ADC)：MRG006A是一款基於新型拓撲異構酶I抑制劑且具有全球FIC潛力的GPC-3靶向ADC候選產品，乃基於Hi-TOPi ADC平台開發。目前正在中國進行HCC的II期臨床試驗。此外，公司獲得FDA的MRG006A IND核准，且該藥物獲FDA授予FTD及ODD認定。I期臨床研究的良好數據已讀出，並計劃於2026年ASCO大會上呈現。MRG007 (CDH17-ADC)：公司與ArriVent正於中國及美國同步進行一項針對不可切除的局部晚期或轉移性實體瘤治療的I期MRCT。於2025年AACR年會上呈現的MRG007的臨床前數據顯示出治療消化道癌的良好臨床潛力。於2025 年1 月，公司與Ar riVent訂立獨家許可協議，據此，公司授予ArriVent在大中華區以外地區開發、製造及商業化MRG007的獨家權利。根據協議條款，公司有資格獲得總計最高達12億美元的首付款及開發、監管及銷售里程碑付款，連同銷售淨額的分級特許權使用費。聯合療法布局：截至2025年12月31日，公司正在進行HNSCC的隨機、開放、多中心III期臨床研究。在美佑恆®與普特利單抗聯合治療方面，公司目前正在進行HNSCC的II期臨床試驗（該試驗已提線至一線治療），其II期臨床試驗的良好數據已於2025年ESMO大會上呈現。公司亦正在歐洲進行針對LA-HNSCC的II期臨床試驗。此外，公司獲得國家藥監局CDE關於在中國開展美佑恆®與普特利單抗聯合療法的IND批准，旨在評估該方案在手術干預前對術前LA-HNSCC患者的療效及安全性。創新平台：公司不斷努力建立和開發新的技術平台，作為公司的創新引擎，同時推動新型創新分子管線的持續進展。公司的研發平台—Hi-TOPi ADC平台及T細胞銜接器平台已成熟並經過驗證。除管線中的在研產品外，公司亦正通過自有研發平台積極開發多特異性抗體IO及多特異性抗體ADC候選藥物。公司計劃於2026年4月的AACR年會上呈現一款雙特異性ADC候選藥物及一款新型免疫腫瘤融合蛋白候選產品的臨床前數據。未來展望：加快後期產品的商業化 加大全球市場拓展力度在藥物研發方面，公司將進一步聚焦於推動下一代ADC藥物及免疫腫瘤雙╱ 三特異性抗體的戰略研發，同時加快後期產品的商業化。此外，公司的核心候選藥物正進入關鍵臨床階段。MRG004A目前正在進行III期臨床試驗的患者入組。CG0070已啟動國內關鍵臨床試驗的患者入組。公司亦將加快推進包括MRG006A及MRG007在內的其他創新候選藥物進入關鍵臨床階段。同時，我們正在不斷探索管線內聯合療法的潛在療效，努力為更廣泛的患者群體帶來更大的臨床效益。在國內商業化方面，公司將繼續集中資源及努力推動商業化進程，專注於提高獲批產品的市場佔有率及銷售表現。公司將採取進一步措施提高這兩款產品的市場可及性，加快各級市場滲透，進一步擴大市場份額。憑藉商業化團隊的專業知識及行業資源，公司將尋求通過市場營銷、學術推廣等各種方式提升品牌形象及市場認知度。同時，公司將根據美佑恆®（注射用維貝柯妥塔單抗）的實際銷售表現優化商業化策略，並利用已全面擴大的營銷及商業化團隊，專注於推動總收入增長。在國際方面，公司將加大在全球市場的拓展力度，堅持不懈地擴大國際網絡，並探索新的業務開發合作機會。公司將繼續致力於在全球範圍內尋找更多戰略合作夥伴，通過合作、授權協議或合營企業等方式開發ADC產品和其他創新候選藥物。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 26, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) (the "Company" or "Casa") is pleased to announce that it has received a large dataset of historic drill hole information from the Congress Gold Mine Project in Yavapai County, Arizona, USA. Comprehensive desktop technical studies integrating this data with the Company's own 2022 drilling campaign have resulted in the identification and delineation of three distinct priority exploration zones that will form the basis of the 2026 field and drilling program.HIGHLIGHTSReceipt of a large historic drill hole database greatly expanding the geological model for the Congress Gold Mine Project3D modelling of over 100 historic and recent drill holes confirms strong structural integrity and continuity of the gold-bearing vein systemsThree distinct exploration zones classified: Echo Bay Exploration Zone (~750m x 1,000m), Malartic Exploration Zone (~450m x 1,150m), and New Congress Niagara Exploration Zone (~800m x 1,000m)Echo Bay Exploration Zone designated highest priority target based on historic drill density and potential for expanded mineralization envelopeHistoric drill intercepts include highlights such as 1.2m @ 43.88 g/t Au, 2.0m @ 21.88 g/t Au, 3.3m @ 27.13 g/t Au, and 11.4m @ 4.81 g/t Au within the Echo Bay ZoneCongress Gold Mine Project is fully permitted with excellent road access and proximity to an experienced regional labor forceCompany geologists and field personnel are being mobilized for initial site preparation and drill program setupHISTORIC DRILL DATABASE COMPILATIONCasa Minerals is pleased to announce the receipt of a comprehensive dataset of historic drill hole collars, surveys, and assay records from the Congress Gold Mine Project. This data was compiled from exploration programs conducted by previous operators -- most notably Echo Bay Mines Ltd. -- during the 1980s through the early 1990s. The database encompasses a significant number of drill holes distributed across the project area, substantially expanding the known geological framework of the property.Historic exploration at the Congress Gold Mine was conducted during a period when gold market conditions were materially lower than today's environment, which directly influenced the selection criteria and cut-off grades used by previous operators. Consequently, the historic programs focused predominantly on higher-grade gold intersections, and many lower-grade vein intercepts that may be economically significant at current gold prices were not assigned the same level of analytical priority. Casa believes this creates a meaningful opportunity to reinterpret the mineralization system with a lower economic threshold, logically expanding the dimensions of the mineralization envelope that will be targeted in the forthcoming drilling season.Important Disclosure: The historic drill hole results referenced in this news release were collected and reported by previous operators under practices that predate current NI 43-101 standards. These results are disclosed solely for contextual and geological interpretation purposes. They have not been verified by a current Qualified Person, do not conform to NI 43-101, and are not classified as current mineral resources or mineral reserves. A Qualified Person has not done sufficient work to classify the historic results as current mineral resources or mineral reserves, and Casa is not treating them as such.THREE-DIMENSIONAL MODELLING AND VEIN SYSTEM VALIDATIONDesktop technical studies have included rigorous 3D modelling of all available drill hole data using industry-standard geological modelling software. The resulting three-dimensional representation of the drill hole database, illustrated in Figure A below, demonstrates the remarkable density of historic drill coverage across the project and confirms the structural coherence and continuity of the principal gold-bearing vein systems.The 3D model was constructed using NAD83 / UTM Zone 12N coordinates and captures drill holes ranging from surface to depths approaching 600 metres below ground elevation. The model reveals that:The dominant vein systems exhibit strong northeast-southwest structural orientation, consistent with the principal fault architecture identified on surfaceThe alignment and attitude of vein structures intercepted in the Company's 2022 confirmatory drilling campaign correlate with high fidelity to those projected from the historic drill hole database, validating the overall geological modelThe 2022 drilling campaign identified additional vein structures not captured in the historic database, indicating that the current geological model is likely incomplete and that the total mineralized footprint may be materially larger than previously understoodIncorporating lower-grade vein intercepts -- previously deprioritized by historic operators under lower gold price conditions -- into the mineralization envelope substantially increases the aggregate target volume for future drillingFigure A: Four-panel 3D presentation of historic and recent drill hole collars and traces, Congress Gold Mine Project. Views from west (upper left), east (upper right), oblique (lower left), and plan (lower right). Coordinate system: NAD83 / UTM Zone 12N. The high density of drill traces illustrates the extensive historic exploration coverage across the project area. Pink/magenta traces represent historic drill holes; black traces represent more recent drilling. Purple lines denote projected vein orientations.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_001full.jpgTHREE PRIORITY EXPLORATION ZONES -- 2026 PROGRAM BASISDetailed integration of the historic drill database with geological mapping, vein system mapping conducted in 2022, and structural interpretation has enabled Casa to formally classify three distinct priority exploration zones within the Congress Gold Mine Project. The classification of each zone reflects the combination of historic drill density, vein system geometry, and the nature of the gold mineralization documented to date. Figures 1 through 4 present these zones in their regional and local contexts.Figure 1: Regional overview map of the Congress Gold Mine Project showing principal vein systems (red dashed), fault corridors (blue dashed), shaft locations (Shafts 1 through 6), historic stope outlines (yellow, 1959-1987), patented claim and BLM claim outlines, and the location of the three principal exploration zones. The project is situated in Yavapai County, Arizona.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_002full.jpgEcho Bay Exploration Zone -- Highest Priority TargetThe Echo Bay Exploration Zone, measuring approximately 750 metres by 1,000 metres, is the largest and most intensively drilled zone on the property. It encompasses the historic non-NI 43-101 resource outline that was previously defined by Echo Bay Mines and represents the core of the historic gold-producing system at Congress. The zone is bounded by the principal northeast-trending veining corridors and is cut by northwest-trending fault structures that locally displace but do not terminate the mineralized vein arrays.As illustrated in Figure 2, the Echo Bay Exploration Zone hosts a dense cluster of historic drill hole intercepts distributed across the full extent of the zone. The drill hole collars and assay intercepts depicted in the figure provide compelling evidence for broad, zone-scale gold mineralization. Notably, the higher-grade intercepts are concentrated along the principal vein corridors while lower-grade disseminated and stockwork gold is documented in the intervening ground. This spatial distribution is characteristic of orogenic gold systems and is consistent with the geological setting at Congress.Selected historic drill intercepts within the Echo Bay Exploration Zone include:1.2m @ 43.88 g/t Au -- exceptional high-grade intercept within the principal vein corridor3.3m @ 27.13 g/t Au -- high-grade intercept demonstrating vein width and continuity2.0m @ 21.88 g/t Au -- high-grade vein intercept in the central portion of the zone2.4m @ 19.03 g/t Au -- confirming strong grade continuity along strike11.4m @ 4.81 g/t Au -- broad, elevated-grade intercept indicative of wide mineralization envelopes within the vein system1.5m @ 15.28 g/t Au -- demonstrating high-grade vein core and broader lower-grade haloes2.0m @ 12.19 g/t Au and 7.3m @ 11.00 g/t Au -- further confirming grade and continuity of the principal vein arrays3.1m @ 11.19 g/t Au and 2.0m @ 15.63 g/t Au -- documented in the southwestern portion of the zone, indicating lateral continuityGiven the historic drill density, the documented grade profile, and the alignment of the 2022 confirmatory drilling with the historic vein model, the Echo Bay Exploration Zone has been assigned the highest exploration priority for the 2026 program. The Company views the zone as offering the clearest near-term pathway to NI 43-101 resource delineation.Figure 2: Detailed plan map of the Echo Bay Exploration Zone (~750m x 1,000m), Congress Gold Mine Project. Shown are historic drill hole intercepts (brown dots annotated with interval length in metres and gold grade in g/t), principal vein system traces (red dashed), fault corridors (blue dashed), historic stope outlines (yellow), shaft locations, and the historic non-NI 43-101 resource outline (red hatch). Selected intercepts include 1.2m @ 43.88 g/t Au, 3.3m @ 27.13 g/t Au, 11.4m @ 4.81 g/t Au, and 2.4m @ 19.03 g/t Au, among numerous others. To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_003full.jpgMalartic Exploration ZoneThe Malartic Exploration Zone covers an area of approximately 450 metres by 1,150 metres and is situated to the south and southeast of the Echo Bay Exploration Zone. The zone is named after the "Malartic-style" stratabound and vein-hosted gold mineralization that has been documented in this area of the project. Historic shaft locations CGC-003 and CGC-004 are located within this zone, providing direct underground access for potential future development.The Malartic Exploration Zone is characterized by multiple subparallel northwest-striking vein sets that have been intercepted in a series of shallow to moderate-depth drill holes. The vein system includes documented vein widths of 27 feet, 38 feet, and 55 feet (as labelled on Figure 3), indicating substantial structural corridors capable of hosting economically significant gold mineralization.Representative historic drill intercepts within the Malartic Exploration Zone include:3.6m @ 0.74 g/t Au and 10.3m @ 1.73 g/t Au -- broad lower-grade intercepts within the principal vein corridor demonstrating wide mineralization envelopes10.36m @ 1.41 g/t Au and 8.1m @ 3.53 g/t Au -- moderate-grade intercepts confirming continuity of the vein arrays7.7 @ 3.56 g/t Au and 8.1m @ 2.53 g/t Au -- further demonstrating consistent grade within vein-hosted mineralization3.2m @ 7.72 g/t Au and 2.8m @ 9.41 g/t Au -- higher-grade intercepts at the northern margin of the zone (shared boundary with the Echo Bay Zone)The Malartic Exploration Zone is relatively underexplored compared to the Echo Bay Zone, and the relatively sparse drill coverage suggests significant upside potential for zone expansion with systematic drilling.Figure 3: Detailed plan map of the Malartic Exploration Zone (~450m x 1,150m), Congress Gold Mine Project. Shown are historic drill hole intercepts (annotated with gold values), principal vein system traces, shaft locations including CGC-003 and CGC-004, historic stope outlines, and documented vein widths of 8.2m, 11.6m, and 16.8m.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_004full.jpgNew Congress Niagara Exploration ZoneThe New Congress Niagara Exploration Zone, measuring approximately 800 metres by 1,000 metres, is the northernmost of the three classified exploration zones and is situated along a structurally distinct corridor characterized by the northwest-striking New Congress-Niagara fault system. This zone encompasses historic Shaft 1 as well as drill holes CGC-008, CGC-009, and CGC-010 from the Company's 2022 exploration program.The 2022 drilling in this zone identified four discrete veins with widths ranging from 49.5 feet to 206 feet -- a notably wide structural corridor. These widths are illustrated in Figure 4 as Vein 49.5 ft, Vein 55 ft, Vein 70.5 ft, and Vein 206 ft. The scale of these structural features highlights the potential for significant bulk-tonnage style mineralization within this zone, distinct from the higher-grade but narrower veins documented in the Echo Bay Zone.Critically, the 2022 drilling at the New Congress Niagara Zone identified several vein structures that are not represented in the historic drill database, reinforcing the Company's view that the existing geological model incompletely captures the full scope of the vein system. This structural incompleteness, combined with the relatively limited historic drill coverage of this zone, underscores its exploration potential.Figure 4: Detailed plan map of the New Congress Niagara Exploration Zone (~800m x 1,000m), Congress Gold Mine Project. Shown are drill hole locations from the 2022 exploration program (CGC-008, CGC-009, CGC-010) alongside Shaft 1, with identified vein widths of 49.5 ft, 55 ft, 70.5 ft, and 206 ft. The purple outline denotes the exploration zone boundary.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_005full.jpgPROJECT STATUS AND 2026 FIELD PROGRAMThe Congress Gold Mine Project is fully permitted for exploration and mining activities in Yavapai County, Arizona. The property benefits from:Fully permitted status: All necessary exploration and access permits are in place, enabling rapid mobilization of field crews and drilling equipmentExcellent road access: Paved and maintained road access to the property boundary facilitates cost-effective equipment and supply logisticsExperienced regional labor force: The Yavapai County region has a well-established mining and exploration workforce with proven experience in gold exploration projects of this typeInfrastructure: Existing shaft infrastructure and historic workings provide geological reference points and potential future development opportunitiesThe Company is currently mobilizing a team of geologists and field personnel to the Congress Gold Mine Project for initial site preparation, geological review, and establishment of the field infrastructure required for the 2026 drilling program. Detailed drill program parameters, including planned hole locations, depths, and targeting rationale, will be provided in a subsequent technical news release.MANAGEMENT COMMENTARY"The receipt of this historic drill database is a genuinely significant development for Casa Minerals," stated Farshad Shirvani, President and CEO. "For the first time, we now have a comprehensive view of the full scope of historic exploration at Congress, and what we see is highly encouraging. The 3D model clearly validates our 2022 findings and demonstrates that the gold system is both continuous and larger than historic estimates suggested. With gold trading at current levels, the lower-grade vein intercepts that were historically deprioritized now become compelling exploration targets in their own right. The Echo Bay Zone, with intercepts like 1.2m @ 43.88 g/t and 11.4m @ 4.81 g/t, gives us a very strong foundation from which to build a modern NI 43-101 resource. We are mobilizing our team and look forward to reporting our first drill results from the 2026 season."QUALIFIED PERSONMr. Erik Ostensoe, P.Geo., a Director and Chief Geologist of the Company, a Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical disclosure in this news release.ABOUT CASA MINERALS INC.Casa Minerals Inc. is a mineral exploration company focused on gold, copper, and strategic minerals exploration in North America. The Company holds a 90% interest in the historic Congress Gold Mine in Arizona and is advancing multiple projects in British Columbia, including the Arsenault copper-gold-silver project. Casa's experienced management team is committed to creating shareholder value through the discovery and development of economic mineral deposits. For more information, please visit: www.casaminerals.comON BEHALF OF THE BOARD OF DIRECTORSFarshad Shirvani, M.Sc. GeologyPresident, CEO and DirectorFor more information, please contact:Casa Minerals Inc.Farshad Shirvani, President & CEOPhone: (604) 678-9587Email: contact@casaminerals.comCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding: the Company's exploration plans and programs for 2026; anticipated drilling activities at the Congress Gold Mine Project; the classification and prioritization of exploration zones; expectations regarding resource definition and the potential to advance the project to NI 43-101 compliant standards; interpretations of historic drill data and 3D geological models; mineralization potential and domain expansion; and mobilization of field personnel. Forward-looking information is based on the opinions and estimates of management at the date the information is made and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated. Such factors include, without limitation: uncertainties regarding exploration results; risks related to the accuracy and completeness of historic data; the inability to verify historic assay results; variations in mineralization and grade; the speculative nature of mineral exploration; challenges in obtaining required permits and approvals; fluctuations in commodity prices; availability of financing; changes in economic and market conditions; environmental and regulatory risks; operating hazards; and other risks inherent in the mineral exploration industry. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290037 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – March 19, AAC Technologies Holdings Inc. (HKEX Stock Code: 2018) held its 2025 Annual Results Announcement Conference in Singapore and reported a strong set of annual results. The Group achieved RMB 31.82 billion in annual revenue, representing a 16.4% year-on-year increase and marking a record high of over RMB 30 billion, with net profit rising 39.8% to RMB 2.51 billion. These results reflect the continued success of the Company’s strategic transformation, with revenue reaching new highs in recent years and net profit delivering sustained double-digit growth.“Pioneering Innovation” and “AI Empowerment” have emerged as the central themes of AAC’s recent developments, driving its strategic transformation from a traditional component supplier to a builder of AI perception infrastructure.In an interview during the conference, AAC’s Chief Financial Officer, Guo Dan, highlighted that the Company’s strategic new business lines — represented by optics and automotive solutions — together with its expansion into high-potential AI sectors such as heat dissipation, robotics, and XR, have become the key growth engines supporting mid-to-long-term sustainable development. This strong momentum is expected to continue unlocking further growth potential in 2026.Looking ahead to 2026, Dan expressed strong confidence. Despite persistent industry volatility, the Group will capitalize on its diversified business portfolio to deliver steady revenue growth, with the growth rate expected to be no lower than that of 2025. At the same time, the gross profit margin is projected to improve steadily from the 22.1% baseline in 2025.( AAC Technologies CFO Guo Dan)1. On the Optics Business: Plastic Lens Gross Margin to Rise to 35%, with Proprietary WLG Technology Reaching Key MilestoneAs a core strategic growth driver, AAC’s optics business (AAC Optics) has achieved rapid development since in 2019. It reported RMB 5.73 billion in revenue in 2025, with a compound annual growth rate (CAGR) exceeding 32% over the past six years, establishing itself as a key pillar of the Group’s overall growth.Dan stated that in 2026, the optics business is expected to deliver steady revenue growth while further improving its gross margin. In 2025, the Company continued to upgrade its mid-to-high-end lens product mix, with the shipments of lens products with 6 or more elements accounting for over 18% of the total and seven-element (7P) lens shipments reaching 15 million units. Building on this foundation, the gross profit margin of plastic lenses is projected to rise from 30% in 2025 to 35% in 2026, reaching a industry-leading level.Notably, AAC has made a significant breakthrough in its globally proprietary Wafer-Level Glass (WLG) lens technology, reaching a key milestone. This advancement not only expands the scope of application scenarios but is also expected to drive a shift in the market landscape traditionally dominated by plastic lenses. Dan added, “In the future, whether in smartphones, automotive solutions, or emerging smart terminal devices, we will see more stable incremental growth that will inject long-term momentum into our business growth.”2. On the Automotive Solution Business: The "Second Growth Engine" Solidifies, with 2026 Revenue Expected to Grow by 15%-20%Through the acquisition of Premium Sound Solutions (PSS), AAC has rapidly established a core platform in the smart automotive solution sector, successfully developing a second growth engine for the Company.Dan revealed that following the acquisition of PSS in 2024 and the acquisitions of Chuguang and PSG in 2025, the Company has become a comprehensive system-level automotive solution provider, expanding its business from smartphones into the entire automotive domain. In 2025, the Company’s automotive acoustics business recorded revenue of RMB 4.12 billion, representing a year-on-year increase of 16.1%. This performance has positioned AAC among the world’s top-tier automotive audio system suppliers, second only to industry leaders such as Harman and Bose.Regarding the 2026 outlook for the automotive acoustics business, Dan stated that the segment is expected to maintain high double-digit growth of 15% to 20%, while keeping the gross margin stable. The Company’s automotive solution business has now achieved broad customer coverage both in China and overseas, including multiple Asian markets. This diversified regional presence is expected to provide steady and reliable support for both revenue and profit growth.3. On AI Sectors: Heat Dissipation Business Poised to Reach RMB 10 Billion, with Explorations in XR and Robotics Opening New FrontiersIf optics and automotive solutions represent the Company’s “core growth engines,” then business lines such as heat dissipation, robotics, and XR optical waveguides constitute the high-potential “reserves” for AAC’s future development. Dan noted that the Company’s revenue in the past was primarily driven by traditional mobile phone acoustics and haptics business. However, following years of strategic transformation and amid broader industry technological shifts, AI has become the fundamental driver underpinning the sustained growth of the Company’s multiple product lines.“For example, the rapid growth of the heat dissipation business is mainly attributable to AI-driven demand. Similarly, our initiatives in robotics and AR glasses are also propelled by AI,” Dan explained. In 2025, the Company’s heat dissipation business recorded revenue of RMB 1.67 billion, grew by 410.9% year-on-year. This performance has further solidified the Company’s position as one of the leading global suppliers in consumer electronics heat dissipation. “As AI technology continues to advance, related application scenarios are expected to extend from smartphones to a wider range of devices, including laptops and tablets, generating strong momentum for the Company’s overall growth.”The acquisition of Yuandi Technology, with more notable strategic significance, has allowed AAC to formally enter the data center liquid cooling, AI server heat dissipation, and high-end thermal solutions sectors, and extend its capabilities from “terminal-side heat dissipation” to “AI infrastructure heat dissipation” creating a synergistic “terminal + infrastructure” development model. Dan stated clearly, “Leveraging the substantial market opportunities across multiple sectors, our heat dissipation business has the potential to reach and even exceed a scale of RMB 10 billion in the coming years, positioning it as a highly promising and important growth engine for the Group.”In the XR optical waveguide field, through the acquisition of Dispelix — a global leader in AR diffractive waveguide technology — AAC has become one of the few industry players with vertically integrated capabilities spanning optical waveguide design and manufacturing. The Company can now offer one-stop full display module solutions, encompassing optical waveguides, optical engines, push-pull lenses, eye-tracking systems, and electrochromic technology. AAC is expected to become the world’s first supplier to achieve mass production of SRG full-color optical waveguides for leading customers in 2026. Dan disclosed, “The per-unit value in the optics business can reach USD 100–200. These initiatives are expected to deliver clear mass production and shipment opportunities within the next two to three years, continuously generating significant value in revenue, profit, and long-term market expansion.”Regarding the robotics field, Dan pointed out that the industry’s market definition, application scenarios, and product forms are still evolving and remain in a diverse exploratory stage. AAC has long maintained deep involvement and has established comprehensive layouts across multiple core areas, including acoustics, motors, optics, structural components, and electromechanics, laying a solid foundation to capture opportunities as the sector matures. “For example, our dexterous hand products for humanoid robots have already entered mass production and shipments, generating over RMB 100 million in revenue last year. In addition, we are co-developing the first motor, as a core component for AI hardware devices, with our customers. Overall, the Company has built deep cooperation with leading domestic and international customers, and we believe we will become an important player in this field in the future.”4. Strategic Review: Combining Technology Reuse with Ecosystem Construction to Anchor Long-Term GrowthIn AAC’s three-decade development journey, the core driver behind its sustained growth has consistently been rooted in the dual logic of technology reuse and ecosystem construction.Leveraging its long-established, robust technological foundations in micro-acoustics, precision optics, electromagnetic drives, sensors, and semiconductors, the Company has successfully upgraded and expanded its business, with its focus shifting from mobile phones and consumer electronics to emerging high-growth areas, including AI terminals, robotics, XR, smart vehicles, and data center infrastructure. This approach enables its core technological capabilities to be efficiently migrated and continuously amplified across diverse application scenarios.This development model — “upgrading application scenarios without changing underlying technology” — not only ensures the stability and success rate of business transformation but also allows the Company to rapidly address capability gaps through strategic ecosystem integration, such as the acquisitions of Dongyang, PSS, Chuguang, and Yuandi. Together, these efforts have created a virtuous cycle of “technology–product–scenario–customer.”The clear pathway to realizing this cycle was articulated by Dan in her outlook: Looking ahead to 2026 and beyond, AAC will position itself as a “builder of AI perception infrastructure,” deepen cross-business synergy and full-scenario coverage, accelerate its expansion into the “AI blue ocean,” strengthen its global footprint, and continue riding the wave of industry development to achieve new heights.source as Forbes（https://www.forbeschina.com/investment/71292） Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com